Shots:

• Sanofi to acquire Amunix for ~$1B up front and is eligible to receive ~$225M upon the achievement of future development milestones. The transaction is expected to close in Q1’22
• The acquisition will use Amunix’s XTEN and Pro-XTEN platform and combine its lead candidate, AMX-818 in Sanofi’s immuno-oncology portfolio to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for cancer patients. Additionally, AMX-818 is expected to enter the clinical phase in early 2022
• The acquisition supports Sanofi’s efforts to expand cancer therapies with ~20 molecules which are currently in development

Click here to­ read the full press release

Ref: Sanofi | Image: Sanofi